SCYNEXIS, a clinical-stage biotech company focused on rare diseases, announced its senior leadership will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference from November 9-11, 2026, in Boston. The company will hold one-on-one meetings and a fireside chat on November 9, which will be webcast live and available for replay. SCYNEXIS is advancing treatments like SCY-770 for polycystic kidney disease and antifungal therapies including BREXAFEMME® and SCY-247. This event offers SCYNEXIS a platform to showcase its innovative pipeline and engage with investors and industry leaders.
SCYNEXIS's upcoming participation in the Guggenheim Healthcare Innovation Conference provides context for health sector activity on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 29, 2026 18:11 WIB: out of 150 priced health-sector US stocks, 95 rose and 47 fell. Notable movers include IOVA at USD 13.40 with a 1-day change of -9.52% and 100% sell order activity, BFLY at USD 8.25 up 5.63%, and THC at USD 254.80 down 5.10%. Typical hold times range from 5 to 17 days across these stocks.
Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...
Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...
Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...
Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...
Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...
